A citation-based method for searching scientific literature

Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
Times Cited: 5







List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
426
60

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
60

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
366
40

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
40

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
437
40

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
355
40

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
152
40

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
40

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
230
40

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
20

GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
K Esposito, C Mosca, C Brancario, P Chiodini, A Ceriello, D Giugliano. Curr Med Res Opin 2011
33
20

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
663
20

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
20

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
783
20


Clinical implications of amylin and amylin deficiency.
D F Kruger, P M Gatcomb, S K Owen. Diabetes Educ 1999
52
20


The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach.
Paolo Pozzilli, R David Leslie, Juliana Chan, Ralph De Fronzo, Louis Monnier, Itamar Raz, Stefano Del Prato. Diabetes Metab Res Rev 2010
73
20


Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
R Moses, R Slobodniuk, S Boyages, S Colagiuri, W Kidson, J Carter, T Donnelly, P Moffitt, H Hopkins. Diabetes Care 1999
165
20

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Rury R Holman, Steven M Haffner, John J McMurray, M Angelyn Bethel, Björn Holzhauer, Tsushung A Hua, Yuri Belenkov, Mitradev Boolell, John B Buse, Brendan M Buckley,[...]. N Engl J Med 2010
303
20

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Samantha L Bowker, Sumit R Majumdar, Paul Veugelers, Jeffrey A Johnson. Diabetes Care 2006
672
20

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Mei Zhang, Lin Zhang, Bin Wu, Haolan Song, Zhenmei An, Shuangqing Li. Diabetes Metab Res Rev 2014
81
20


The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.
Diana Sherifali, Kara Nerenberg, Eleanor Pullenayegum, Ji Emmy Cheng, Hertzel C Gerstein. Diabetes Care 2010
186
20




Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
Yanbing Li, Wen Xu, Zhihong Liao, Bin Yao, Xiahua Chen, Zhimin Huang, Guoliang Hu, JianPing Weng. Diabetes Care 2004
199
20

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
20



Refining basal insulin therapy: what have we learned in the age of analogues?
J H Devries, M Nattrass, T R Pieber. Diabetes Metab Res Rev 2007
73
20

Glucagon-like peptide-1: a potent regulator of food intake in humans.
J P Gutzwiller, B Göke, J Drewe, P Hildebrand, S Ketterer, D Handschin, R Winterhalder, D Conen, C Beglinger. Gut 1999
412
20

Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Neda Rasouli, Ulrika Raue, Leslie M Miles, Tong Lu, Gina B Di Gregorio, Steven C Elbein, Philip A Kern. Am J Physiol Endocrinol Metab 2005
107
20


Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Adriaan Kooy, Jolien de Jager, Philippe Lehert, Daniël Bets, Michiel G Wulffelé, Ab J M Donker, Coen D A Stehouwer. Arch Intern Med 2009
244
20

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A DeFronzo. Diabetes Care 2016
184
20

GLP-1 based therapies: differential effects on fasting and postprandial glucose.
M S Fineman, B B Cirincione, D Maggs, M Diamant. Diabetes Obes Metab 2012
82
20

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
618
20

Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes.
Hitoshi Sugihara, Mototsugu Nagao, Taro Harada, Yasushi Nakajima, Kyoko Tanimura-Inagaki, Fumitaka Okajima, Hideki Tamura, Takeshi Inazawa, Takatoshi Otonari, Masanobu Kawakami,[...]. J Diabetes Investig 2014
23
20

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Ulrich Werner, Guido Haschke, Andreas W Herling, Werner Kramer. Regul Pept 2010
115
20

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
E Näslund, B Barkeling, N King, M Gutniak, J E Blundell, J J Holst, S Rössner, P M Hellström. Int J Obes Relat Metab Disord 1999
313
20

Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
J M Jonasson, R Ljung, M Talbäck, B Haglund, S Gudbjörnsdòttir, G Steineck. Diabetologia 2009
308
20

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Philippe Vague, Jean-Louis Selam, Svein Skeie, Ivo De Leeuw, Jan W F Elte, Hanne Haahr, Allan Kristensen, Eberhard Draeger. Diabetes Care 2003
200
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.